 GAITHERSBURG, Md., Sept. 27, 2021 GLOBE NEWSWIRE -- Altimmune, Inc. Nasdaq: ALT, a clinical-stage biopharmaceutical company, today announced that it will report the results from its 12-week Phase 1 clinical trial of ALT-801 in overweight and obese subjects in a pre-market press release and webcast to be held on Tuesday, September 28, 2021. 